Fiche centre
Yokohama City University Hospital
Yokohama — Japan
Essais liés12clinical trials
VilleYokohamalocalisation
PaysJapanlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07164443
Essais cliniques associés
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BI 690517 | Maladie rénale chronique | Phase 3 | NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | ACTIVE_NOT_RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT05980949 | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | RECRUITING |
| Pasritamig | Cancer | Phase 3 | NCT07164443 | KLK2-comPAS — A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | RECRUITING |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT05151471 | Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED |
| Emapalumab | Lupus | Phase 3 | NCT05001737 | EMERALD — Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | COMPLETED |
| KarXT | Alzheimer | Phase 3 | NCT06585787 | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | RECRUITING |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04165824 | Safety Study of Oral Edaravone Administered in Subjects With ALS | COMPLETED |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04577404 | Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT05568615 | Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS | COMPLETED |
| CC-97540 | Lupus | Phase 2 | NCT07015983 | A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | ACTIVE_NOT_RECRUITING |
| BIIB059 (litifilimab) | Lupus | Phase 3 | NCT06044337 | AMETHYST LTE — A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | ENROLLING_BY_INVITATION |
| Litifilimab | Lupus | Phase 2/3 | NCT05531565 | AMETHYST — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING |